Tesevatinib has been used in trials studying the treatment of Cancer, Stomach Cancer, Brain Metastases, Esophageal Cancer, and Leptomeningeal Metastases, among others.
Tesevatinib is a potent inhibitor of multiple RTKs implicated in driving tumor cell proliferation and tumor vascularization (blood vessel formation). Tesevatinib inhibits the EGF, HER2, and VEGF RTKs, each of which is a target of currently approved cancer therapies. In addition, tesevatinib inhibits EphB4, an RTK that is highly expressed in many human tumors and plays a role in promoting angiogenesis. In a broad array of preclinical tumor models including breast, lung, colon and prostate cancer, XL647 demonstrated potent inhibition of tumor growth and causes tumor regression. In cell culture models, tesevatinib retains significant potency against mutant EGFRs that are resistant to current EGFR inhibitors.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Acetaminophen | The serum concentration of Acetaminophen can be increased when it is combined with Tesevatinib. |
| Propacetamol | The serum concentration of Propacetamol can be increased when it is combined with Tesevatinib. |
| Salmon calcitonin | The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Tesevatinib. |
| Thyrotropin alfa | The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Tesevatinib. |
| Follitropin | The therapeutic efficacy of Follitropin can be decreased when used in combination with Tesevatinib. |
| Liothyronine | The therapeutic efficacy of Liothyronine can be decreased when used in combination with Tesevatinib. |
| Carbimazole | The therapeutic efficacy of Carbimazole can be decreased when used in combination with Tesevatinib. |
| Levothyroxine | The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Tesevatinib. |
| Propylthiouracil | The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Tesevatinib. |
| Methimazole | The therapeutic efficacy of Methimazole can be decreased when used in combination with Tesevatinib. |
| Liotrix | The therapeutic efficacy of Liotrix can be decreased when used in combination with Tesevatinib. |
| 3,5-Diiodotyrosine | The therapeutic efficacy of 3,5-Diiodotyrosine can be decreased when used in combination with Tesevatinib. |
| Tiratricol | The therapeutic efficacy of Tiratricol can be decreased when used in combination with Tesevatinib. |
| Parathyroid hormone | The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Tesevatinib. |
| Teriparatide | The therapeutic efficacy of Teriparatide can be decreased when used in combination with Tesevatinib. |
| Potassium Iodide | The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Tesevatinib. |
| Dibromotyrosine | The therapeutic efficacy of Dibromotyrosine can be decreased when used in combination with Tesevatinib. |
| Thyroid, porcine | The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Tesevatinib. |
| Potassium perchlorate | The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Tesevatinib. |
| Protirelin | The therapeutic efficacy of Protirelin can be decreased when used in combination with Tesevatinib. |
| 3,5-diiodothyropropionic acid | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Tesevatinib. |
| Methylthiouracil | The therapeutic efficacy of Methylthiouracil can be decreased when used in combination with Tesevatinib. |
| Elcatonin | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Tesevatinib. |
| Benzylthiouracil | The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Tesevatinib. |
| Thyrotropin | The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Tesevatinib. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tesevatinib. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tesevatinib. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Tesevatinib. |
| Methoxy polyethylene glycol-epoetin beta | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tesevatinib. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Quinisocaine. |
| Voriconazole | The serum concentration of Tesevatinib can be increased when it is combined with Voriconazole. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Tesevatinib. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Tesevatinib is combined with Ambroxol. |
| Etrasimod | The risk or severity of immunosuppression can be increased when Tesevatinib is combined with Etrasimod. |
| Palopegteriparatide | The therapeutic efficacy of Palopegteriparatide can be decreased when used in combination with Tesevatinib. |